@ARTICLE{
author={Davies Andrew,Merli Francesco,Mihaljevic Biljana S,Mercadal Santiago,Siritanaratkul Noppadol,Solal-Celigny Philippe,Boehnke Axel,Berge Claude,Genevray Magali,Zharkov Artem,Dixon Mark,Brewster Michael,Barrett Martin,MacDonald David},
year={2017},
title={Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial},
journal={LANCET HAEMATOLOGY},
volume={4},
number={6},
pages={E272-E282},
document_type={Article},
} 

@ARTICLE{
author={Davies Andrew J,Mihaljevic Biljana S,Mercadal Santiago,Mihaylov Georgi,Leppa Sirpa,Cotting Denise,Veenstra Klaas,Zharkov Artem,Dixon Mark,Barrett Martin,Macdonald David},
year={2016},
title={Longer Term Efficacy and Safety of Subcutaneous Compared with Intravenous Rituximab: Updated Results of the Phase 3 SABRINA Study},
journal={BLOOD},
volume={128},
number={22},
pages={-},
document_type={Meeting Abstract},
}